Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience

Blinatumomab is a bispecific anti-CD3 and anti-CD19 antibody that acts as a T-cell engager: by binding CD19+ lymphoblasts, blinatumomab recruits cytotoxic CD3+ T-lymphocytes to target the cancer cells. Here we describe seven different patients affected by B-cell precursor acute lymphoblastic leukemi...

Full description

Bibliographic Details
Main Authors: Andrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro, Marina Parisi, Cinzia Maugeri, Paolo Fabio Fiumara, Giuseppe Milone, Alessandra Romano, Francesco Di Raimondo, Salvatore Leotta
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
blinatumomab
T-cell kinetics
minimal residual disease
acute lymphoblastic leukemia
cytokines
MDSCs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1195734/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1195734/full

Similar Items